Certify Before You Buy—How To Deal With New Machinery

Derek DeGeest, President of DeGeest Corporation and LestaUSA, knows when the industry comes together to help each other, successful integration of robotics and automation into operations follows. After being on both sides of the coin of installing a large finishing system and shepherding in new self-learning robotic technology to North America, it’s important to share the combined experiences of DeGeest Corp and LestaUSA to help manufacturing grow.

DeGeest wants to encourage other general industry manufacturers to bring new machinery into their operations. But, there is also a cautionary tale to be told. DeGeest shared his company’s ulcer-inducing experience and learnings when, as a contract job shop, they installed a large finishing system. A new state regulatory interpretation on machinery vs equipment almost shut down the entire system.

Without certification, the machinery was useless. “We had to find a way to learn the regulatory system and work with every group to find a solution,” DeGeest said. “And we did. Fast forward, three years later, we now have the largest robotic painting system in the contract job shop world in North America.”

DeGeest also walks through the process of getting Lesta’s robot technology NRTL certified and the importance of having this certification in North America. Launching Lesta’s proven robotic system’s in North America proved to need a different set of classifications than European standards that required multiple system changes.

DeGeest recognized when dealing with new machinery and equipment in the marketplace; regulators have an impossible task. “Changing technology in manufacturing is so fast that it doesn’t keep up with the code, and it is hard for them (the regulators) to interpret how they’re supposed to apply that to the new machinery that’s coming out,” DeGeest said. “That’s what happened to us. Our machinery was newly interpreted as equipment according to the codebook, so they didn’t know what to do.” DeGeest worked with the regulators to hammer out a solution, rewrite the code, and create a path forward for other industry companies. Why? Because at DeGeest Corporation and Lesta USA, they believe a rising tide lifts all boats.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

AMAG Technology
AMAG Technology: Control, Reliability, and Customer-First Supply Chain Excellence
April 2, 2025

At AMAG Technology, being customer-obsessed goes beyond a mindset—it’s built into every part of the operation. One of the company’s greatest strengths lies in its ability to manufacture its own products, offering a level of supply chain control that few competitors can match. Allan Price, Head of Global Supply Chain at AMAG, emphasizes how this…

Read More
visitor management solution
Reinventing Visitor Management Solution with Symmetry GUEST
April 2, 2025

In an age where speed and security are paramount, the traditional paper logbook is becoming a relic of the past. AMAG Technology’s Symmetry Guest system offers a modern, digital solution that redefines the way organizations welcome and manage visitors. Gone are the days of long lines and confusion at the front desk—Symmetry Guest empowers hosts…

Read More
AMAG
Driven by Customers, Defined by Innovation: Inside AMAG’s Customer-Obsessed Approach
April 2, 2025

AMAG Technology continues to strengthen its customer-obsessed culture by actively listening to both internal and external voices. As shared by Kyle Gordon, Executive Vice President of Global Sales, Marketing, & Commercial Excellence, the company is focused on improving processes, responding with speed, and driving innovation—while honoring its legacy and delivering unique value within the industry.

Read More
biotech
Biotech Moves Smarter: IDDI Powers Data-Driven Drug Innovation
April 2, 2025

As biotech innovation accelerates, small and mid-size pharmaceutical companies are becoming key players in bringing new treatments to market. Yet many of these organizations face steep challenges when navigating clinical trial design, regulatory approval, and data integrity. According to a McKinsey Global Institute report, industries like biotech could help generate up to $50 trillion…

Read More